PMV PHARMACEUTICALS INC (PMVP)
US69353Y1038 - Common Stock
We assign a fundamental rating of 3 out of 10 to PMVP. PMVP was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PMVP as it has an excellent financial health rating, but there are worries on the profitability. PMVP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PMVP has reported negative net income.
PMVP had a negative operating cash flow in the past year.
In the past 5 years PMVP always reported negative net income.
In the past 5 years PMVP always reported negative operating cash flow.
1.2 Ratios
PMVP has a better Return On Assets (-23.03%) than 73.81% of its industry peers.
The Return On Equity of PMVP (-26.00%) is better than 81.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.03% | ||
| ROE | -26% | ||
| ROIC | N/A |
ROA(3y)-23.97%
ROA(5y)-21.19%
ROE(3y)-26.37%
ROE(5y)-22.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PMVP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PMVP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PMVP has been increased compared to 5 years ago.
PMVP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.70, we must say that PMVP is in the distress zone and has some risk of bankruptcy.
PMVP has a Altman-Z score of -0.70. This is comparable to the rest of the industry: PMVP outperforms 59.65% of its industry peers.
PMVP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.7 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.98 indicates that PMVP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.98, PMVP belongs to the top of the industry, outperforming 88.14% of the companies in the same industry.
PMVP has a Quick Ratio of 13.98. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.98, PMVP belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.98 | ||
| Quick Ratio | 13.98 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.31% over the past year.
EPS 1Y (TTM)36.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 10.89% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.72%
EPS Next 2Y-6.05%
EPS Next 3Y-5.43%
EPS Next 5Y10.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PMVP. In the last year negative earnings were reported.
Also next year PMVP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as PMVP's earnings are expected to decrease with -5.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.05%
EPS Next 3Y-5.43%
5. Dividend
5.1 Amount
No dividends for PMVP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PMV PHARMACEUTICALS INC
NASDAQ:PMVP (1/14/2025, 8:00:01 PM)
After market: 1.36 +0.01 (+0.74%)1.35
-0.04 (-2.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.63%
Inst Owner Change0%
Ins Owners2.27%
Ins Owner Change-0.08%
Market Cap69.86M
Analysts86.67
Price Target7.99 (491.85%)
Short Float %3.05%
Short Ratio6.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)45.53%
Min EPS beat(2)-3.35%
Max EPS beat(2)94.4%
EPS beat(4)3
Avg EPS beat(4)32.68%
Min EPS beat(4)-3.35%
Max EPS beat(4)94.4%
EPS beat(8)7
Avg EPS beat(8)23.94%
EPS beat(12)10
Avg EPS beat(12)16.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.03% | ||
| ROE | -26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-23.97%
ROA(5y)-21.19%
ROE(3y)-26.37%
ROE(5y)-22.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 54.1% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.98 | ||
| Quick Ratio | 13.98 | ||
| Altman-Z | -0.7 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1001.92%
Cap/Depr(5y)616.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.82%
EPS Next Y25.72%
EPS Next 2Y-6.05%
EPS Next 3Y-5.43%
EPS Next 5Y10.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.06%
EBIT Next 3Y-13.88%
EBIT Next 5YN/A
FCF growth 1Y29.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.76%
OCF growth 3YN/A
OCF growth 5YN/A